• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evogene Schedules First Quarter 2025 Financial Results Release

    5/8/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email

    Zoom conference call scheduled for May 21, 2025, 9:00 AM ET

    REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.

    Evogene Logo

    Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

    To join the conference, please register in advance:

    https://www.veidan-conferenceing.com/evogene

    The entire conference will be available online on the company's website a few days after.

    About Evogene:

    Evogene Ltd. (NASDAQ:EVGN, TASE: EVGN)) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

    Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

    Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

    1. Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
    2. Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
    3. AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
    4. Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.

    For more information, please visit: www.evogene.com.

    Contact

    [email protected]

    Tel: +972-8-9311901

    Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2025-financial-results-release-302449812.html

    SOURCE Evogene

    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

      The new model addresses the challenge of identifying novel small molecules that meet multiple product criteria, an essential requirement for pharma and agriculture applications REHOVOT, Israel, June 10, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing life-science product discovery and development, today announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud. The new model expands the existing capabilities of ChemPass AI, Evogene's tech-engine for small molecule discovery and optimization, by addressing one of the core c

      6/10/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports First Quarter 2025 Financial Results

      Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe

      5/21/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      6/17/25 4:01:10 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      6/5/25 4:01:04 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      5/21/25 7:00:40 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

      RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

      11/24/21 7:31:39 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Evogene with a new price target

      ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

      10/8/21 8:30:09 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

      RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

      8/23/21 11:09:14 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials